References
- The Leukemia & Lymphoma Society. Chronic Myelogenous Leukemia. http://www.lls.org/#/diseaseinformation/leukemia/chronicmyeloidleukemia/incidence/. Accessed March 14, 2012
- American Cancer Society. What are the key statistics about chronic myeloid leukemia? http://www.cancer.org/Cancer/Leukemia-ChronicMyeloidCML/DetailedGuide/leukemia-chronic-myeloid-myelogenous-key-statistics. Accessed June 23, 2011
- US Food and Drug Administration: Imatinib. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021588s035lbl.pdf. Accessed May 22, 2012
- US Food and Drug Administration: Nilotinib. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022068s012lb.pdf. Accessed May 22, 2012
- US Food and Drug Administration: Dasatinib. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021986s009s010lbl.pdf. Accessed May 22, 2012
- Moen MD, McKeage K, Plosker GL, et al. Imatinib: a review of its use in chronic myeloid leukaemia. Drugs 2007;67:299-320
- Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-17
- Reed SD, Anstrom KJ, Li Y, et al. Updated estimates of survival and cost effectiveness for imatinib versus interferon-alpha plus low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukaemia. Pharmacoeconomics 2008;26:435-46
- Kelly K, Swords R, Mahalingam D, et al. Serosal inflammatio n (pleural and pericardia l effusions) related to tyrosine kinase inhibitors. Targ Oncol 2009;4:99-105
- Masiello D, Gorospe G, 3r dYang AS. The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib. J Hematol Oncol 2009;2:46
- Breccia M, Alimena G. Pleural/pericardic effusions during dasatinib treatment: incidence, management and risk factors associated to their development. Expert Opin Drug Saf 2010;9:713-21.
- Porkka K, Khoury HJ, Paquette, RL, et al. Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. Cancer 2010 Jan 15;116(2):377-86
- Froudarakis M. Diagnostic work-up of pleural effusions. Thematic Review Series 2008. Respiration 2008;75:4-13
- van den Toorn LM, Schaap E, Surmont VF, et al. Management of recurrent malignant pleural effusions with a chronic indwelling pleural catheter. Lung Cancer 2005 Oct;50(1):123-7
- Schulze M, Boehle AS, Kurdow R, et al. Effective treatment of malignant pleural effusion by minimal invasive thoracic surgery: thoracoscopic talc pleurodesis and pleuroperitoneal shunts in 101 patients. Ann Thorac Surg 2001;71:1809-12
- Darkow T, Henk HJ, Thomas SK, et al. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmacoeconomics 2007;25:481-96
- Wu EQ, Johnson S, Beaulieu N, et al. Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients. Curr Med Res Opin 2010;26:61-9
- Wu EQ, Bollu VK, Guo A, et al. Non-adherence to imatinib in chronic myeloid leukemia patients is associated with a short term and long term negative impact on healthcare utilization and costs. Blood (ASH Annual Meeting Abstracts) 2009;114:4270
- Marin D, Bazeos A, Mahon FX, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 2010;28:2381-8
- Stephens J, Carpiuc KT, Botteman M. The burden of managing pleural effusions in patients with chronic myelogenous leukemia post-imatinib failure: a literature-based economic analysis. Int J Gen Med 2010;3:31-6
- Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-9
- Elixhauser A, Steiner C, Harris DR, et al. Comorbidity measures for use with administrative data. Med Care 1998;36:8-27
- US Food and Drug Administration. Imatinib mesylate. www.accessdata.fda.gov/drugsatfda_docs/label/2009/021588s026s028lbl.pdf. Accessed November 4, 2010
- US Food and Drug Administration. Dasatinib. www.accessdata.fda.gov/drugsatfda_docs/label/2009/021986s004lbl.pdf. Accessed November 4, 2010
- US Food and Drug Administration: Nilotinib hydrochloride monohydrate. Avaliable at: www.accessdata.fda.gov/drugsatfda_docs/label/2010/022068s004s005lbl.pdf [Last accessed Nov 4 2010]
- United States Department of Labor. Bureau of Labor Statistics. Medical Consumer Price Index. www.bls.gov/data/#prices. Accessed November 17, 2010
- Quintás-Cardama A, Kantarjian H, O'brien S, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 2007;25:3908-14
- Noens L, van Lierde M, De Bock R, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 2009;113:5401-11
- Light RW. Pleural effusion. N Engl J Med 2002;346:1971-7
- University of Maryland, Medical Center. Pleural effusion – Overview. www.umm.edu/ency/article/000086.htm. Accessed November 18, 2010
- U.S. National Library of Medicine, Medline plus. Heart failure. www.nlm.nih.gov/medlineplus/ency/article/000158.htm. Accessed November 18, 2010
- Krauth MT, Herndlhofer S, Schmook MT, et al. Extensive pleural and pericardial effusion in CML during treatment with dasatinib at 100 mg or 50 mg daily. Haematologica 2011;96:163-6